Executive Summary
By mid-2026, the IL-4 and IL-13 field has moved beyond a one-brand story. One broad dual-pathway franchise now spans multiple specialties, while selective IL-13 antibodies and a China-based IL-4Rα entrant are building narrower but credible positions.
The strategic split is increasingly clear. Receptor-level blockade is winning on indication breadth and platform scale, while selective IL-13 programs are competing through focused dermatology positioning, lifecycle management, and next-wave expansion into younger patients or new diseases.
Continue Reading
The Executive Summary is available to all readers. Sign in to any account to unlock the full insights page, including the detailed analysis, market landscape, and source-backed section breakdowns.